When Migraines Won't Let Go
Migraine is the second leading cause of disability worldwide. The disabling symptoms — pain, sensitivity to light and sound, nausea and vomiting — can disrupt work, family life, and basic daily function. For most people, acute medications or standard preventive treatments provide enough relief to regain control. But for a significant minority, standard approaches fail.
These stubborn cases are known as refractory migraines: severe attacks that persist despite appropriate treatment. An estimated 5-30% of chronic migraine sufferers — 2 to 12 million people in the U.S. — experience this form. Refractory migraine is defined as episodes that do not respond to preventive therapies, with headaches occurring eight or more days per month and causing significant disability.
For decades, preventive care relied on borrowed medications — antidepressants, blood pressure medicines, and antiseizure drugs. These were not designed for migraine and often fell short. More than half of patients discontinue these older treatments within three months due to limited effectiveness or side effects.
The past decade has transformed the landscape. Targeted migraine therapies now address the underlying biology. These include CGRP monoclonal antibodies and gepants, which block the chemical messenger calcitonin gene-related peptide involved in migraine attacks. OnabotulinumtoxinA (Botox), approved in 2010, prevents the release of CGRP and other pain-related molecules from sensory nerves. Neuromodulation devices provide drug-free relief by altering how pain signals are processed. For the most treatment-resistant cases, surgical interventions such as nerve decompression and occipital nerve blocks offer additional options.
The California Pain Institute in Los Angeles brings these modern options together under one roof. Patients with debilitating, treatment-resistant migraines can access a full range of targeted therapies, from CGRP-blocking medications and Botox to advanced interventional procedures, all tailored to their specific needs.
Understanding Chronic Migraine
Chronic migraine is a distinct and severe classification of the disorder defined by headache frequency. A person is diagnosed with chronic migraine when they experience headaches on 15 or more days per month for more than three months, with migraine-specific features such as throbbing pain, aura, or sensitivity to light and sound occurring on at least eight of those days. This is a significant departure from episodic migraine, where attacks happen on fewer than 15 headache days each month.
The progression from episodic to chronic migraine is a real risk. Research from the European Headache Federation estimates that up to 3% of patients with episodic migraine make this transition each year. Recognized risk factors accelerating this shift include female sex, high initial attack frequency, medication overuse, and comorbid conditions such as depression, anxiety, and obesity.
Accurate diagnosis relies on the International Classification of Headache Disorders (ICHD-3) criteria and a detailed headache diary maintained by the patient. A thorough medical evaluation by a headache specialist is needed to rule out secondary causes and confirm the sustained high-frequency pattern. For patients in Los Angeles, the team at capaininstitute.com uses this approach to create targeted management plans.
The Refractory Migraine Subset
A small but severely affected subset of chronic migraine patients experience refractory migraines. Stony Brook Medicine describes these as treatment-resistant migraines occurring on eight or more days per month that do not respond to standard preventive or acute therapies. An estimated 2 to 12 million people in the U.S. fall into this category, suffering persistent symptoms despite medical intervention.
From Pain Relief to Targeted Prevention
Migraine treatment is typically divided into two categories: acute (abortive) therapy, taken during an attack to stop symptoms, and preventive (prophylactic) therapy, taken regularly to reduce the frequency and severity of attacks. Acute medications work best when taken as soon as symptoms begin, which is why many patients keep options like ibuprofen or a combination of acetaminophen, aspirin, and caffeine (often sold as Excedrin Migraine) on hand.
Acute Treatment Options
For mild migraines, over-the-counter pain relievers such as aspirin, ibuprofen, and naproxen can be effective. For moderate to severe attacks, triptans are a prescription first-line treatment. Triptans like sumatriptan and rizatriptan work by blocking pain pathways in the brain. They come in various forms, including pills, dissolvable tablets, nasal sprays, and injections, allowing patients to choose the fastest-acting option.
However, triptans are not safe for everyone, particularly those with a history of stroke, heart attack, or coronary artery disease. Newer acute options like lasmiditan (a ditan) and oral gepants such as ubrogepant and rimegepant were developed to fill this gap. These newer medications do not cause blood vessel constriction, making them a safer alternative for patients with cardiovascular risk factors. Patients in the Los Angeles area can discuss these options with a specialist at the Cedars-Sinai Headache Clinic, which offers evidence-based acute and interventional treatments.
When to Consider Preventive Therapy
The goal of preventive therapy is to reduce the number of headache days and improve daily function. This approach is typically recommended for patients who experience four or more headache days per month, or whose attacks cause significant disability despite optimal acute treatment.
Historically, preventive care relied on medications borrowed from other conditions, such as certain antidepressants (e.g., topiramate) and beta-blockers (e.g., propranolol). However, the American Migraine Foundation notes that over half of patients discontinue these older treatments within three months due to limited effectiveness or side effects. Today, the landscape has changed dramatically with the arrival of CGRP-targeted therapies, which are now considered first-line options for prevention by the American Headache Society. At capaininstitute.com, a pain specialist can help match your migraine pattern to the most appropriate preventive strategy, whether that involves an older medication, a CGRP monoclonal antibody, or a non-pharmacological approach like Botox or neuromodulation.
The CGRP Revolution in Migraine Care
The discovery that calcitonin gene-related peptide (CGRP) is a central chemical messenger in migraine pain transmission has led to the first class of medications designed specifically for migraine. Unlike older preventive drugs borrowed from other conditions, CGRP-targeted therapies directly interrupt the pain signaling pathway at its source.
Two Classes of CGRP-Targeting Therapies
Monoclonal antibodies. These lab-made proteins block CGRP or its receptor. Four are FDA-approved for prevention: erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality) are self-injected monthly or quarterly; eptinezumab (Vyepti) is given as an IV infusion every three months.
Gepants. These oral small molecules act as CGRP receptor antagonists. Rimegepant (Nurtec ODT) works for both acute and preventive use. Atogepant (Qulipta) is a daily preventive pill. Ubrogepant (Ubrelvy) and zavegepant (Zavzpret, a nasal spray) are approved for acute treatment.
First-Line Recommendation and Real-World Advantages
The American Headache Society now considers anti-CGRP therapies a first-line option for both episodic and chronic migraine. Because these drugs target migraine specifically, they often cause fewer side effects than older preventives and can be effective when other treatments have failed. Reported side effects include injection site reactions, constipation, and fatigue, but they are generally well tolerated.
However, insurance plans frequently require patients to try older medications first before covering CGRP therapies. Safety during pregnancy is unknown, so family planning should be discussed with a doctor. For patients in the Los Angeles area, the California Pain Institute can evaluate whether a CGRP-targeted option is appropriate for your migraine pattern and help navigate insurance requirements.
Botox: An Established Preventive Option
For patients with chronic migraine, onabotulinumtoxinA (Botox) offers a well-established, non-pharmaceutical preventive option. The FDA approved Botox for chronic migraine prevention in 2010, specifically for those experiencing 15 or more headache days per month, with at least 8 of those days being migraine days lasting 4 hours or longer.
Botox works by preventing the release of CGRP and other pain-related molecules from sensory nerves, in addition to its well-known muscle-weakening effect. The treatment protocol involves 31 injections across specific points in the head and neck, administered every 12 weeks in a healthcare professional's office.
Patients typically see a reduction of 8 to 9 headache days per month, with initial results visible within 4 weeks and continued improvement over 24 weeks. Common side effects include injection site pain, bruising, neck discomfort, and temporary cosmetic effects such as eyelid drooping. The safety of Botox during pregnancy is unknown, and the requirement for in-office treatment every three months can be challenging for those living far from a provider.
At the California Pain Institute, Dr. Magued Fadly and his team are experienced in administering Botox for chronic migraine, helping patients in the Los Angeles area access this established treatment. Scheduling a consultation can determine if Botox is the right approach for your situation.
Drug-Free Relief: Neuromodulation Devices
For patients seeking a non-pharmacologic path to migraine control, neuromodulation provides a distinctive option. These noninvasive devices stimulate specific nerves connected to migraine pathways, altering how the brain processes pain signals. They are generally well-tolerated, with side effects typically limited to mild discomfort at the stimulation site.
Five FDA-Cleared Options
eTNS (Cefaly). External trigeminal nerve stimulation to reduce migraine frequency and severity.
eVNS (Gammacore). External vagal nerve stimulation for acute and preventive migraine treatment.
sTMS (SAVI Dual). Single-pulse transcranial magnetic stimulation designed to both prevent attacks and relieve acute migraine pain.
eCOT-NS (Relivion MG). External combined occipital and trigeminal nerve stimulation that targets multiple nerve pathways.
REN (Nerivio). Remote electrical neurostimulation worn on the upper arm, used for acute treatment, and controlled via a smartphone app.
Some devices are cleared for acute treatment during an attack, others for daily preventive use, and a few can serve both roles.
Practical Benefits and Limitations
Neuromodulation is especially appropriate for individuals who cannot take standard migraine medications, including those concerned about pregnancy. However, these devices are usually not covered by insurance, resulting in high out-of-pocket expenses. They are also not recommended for people with uncontrolled epilepsy or implanted medical devices.
While neuromodulation adds a drug-free tool to the migraine toolkit, it is often combined with other strategies. Clinics like capaininstitute.com offer a comprehensive evaluation to determine whether a device-based approach, medication adjustments, or a combination of both best fits each patient's situation.
When Stubborn Migraines Need More
For a subset of people with chronic migraine, standard preventive therapies and acute medications fail to provide adequate relief. These severe, treatment-resistant attacks are known as refractory migraines. They are characterized by persistent and frequent symptoms, with severe headaches occurring eight or more days per month, despite attempts at treatment. It is estimated that 2-12 million people in the U.S. are affected by this condition.
For patients whose migraines do not respond to the first-line and second-line options discussed earlier, a minimally invasive outpatient procedure called intra-arterial lidocaine infusion offers a new avenue. The procedure involves infusing lidocaine, a numbing medication, directly into the middle meningeal arteries — the blood vessels supplying the outer coverings of the brain, a pain-sensitive area linked to migraines. A catheter is placed through an artery near the right wrist, and the infusion takes approximately 30 minutes under light sedation. In many patients, this treatment provides immediate relief that can last for a month or longer. An added benefit is that it can enhance the effectiveness of a patient's other migraine medications.
Other Options for Refractory Cases
Several other interventions can address treatment-resistant migraine pain. Occipital nerve blocks, which involve injecting an anesthetic near the occipital nerves at the back of the head, can reduce pain. Trigger point injections target focal muscle spasms to alleviate discomfort. For some patients, adjustments to their medication regimen, including trying a different class of preventive drugs or combining therapies, can break the cycle of stubborn attacks.
Surgical Solutions for Lasting Relief
For a subset of patients, even the best preventive medications, nerve blocks, and Botox injections fail to provide adequate relief. When the underlying anatomy itself contributes to migraine pain, a surgical approach may offer a lasting solution.
Occipital Nerve Decompression Surgery
Occipital nerve decompression surgery targets the occipital nerves—a network of nerves at the back of the head that, when compressed or inflamed, can trigger or worsen migraine pain. The procedure is typically considered only after other treatments have been exhausted. It involves a small incision behind the hairline at the base of the neck, through which the surgeon gently releases the nerve from surrounding pressure. The goal is to restore normal nerve function and reduce the frequency and severity of attacks.
Outcomes reported in the literature are encouraging. Studies cited by Migraine Disorders show that occipital nerve decompression can result in complete migraine elimination for 28 to 59 percent of patients, and a reduction of more than 50 percent for many others. These results position surgery as a meaningful option for those with refractory migraine who have not responded to other interventions.
For those in the Los Angeles area, specialized centers offer this procedure. The California Pain Institute provides comprehensive evaluations to determine if nerve decompression is appropriate, and migraine surgery centers in the region offer similar expertise. Consulting with a pain specialist who understands the full range of treatment options is a valuable step for patients who continue to struggle despite maximal therapy.
Lifestyle and Home Management Strategies
Living with chronic migraine often means combining medical treatments with proactive daily habits to reduce attack frequency and severity. Many people find the SEEDS approach helpful: consistent Sleep, regular Exercise, a healthy Eating routine, keeping a Diary to track triggers, and Stress management. These strategies help minimize environmental triggers and give patients a greater sense of control. Specialists at the California Pain Institute work with patients to integrate these approaches into a comprehensive plan.
Creating a Calm Environment During Attacks
When a migraine strikes, a few simple home treatments can offer relief. Head to a quiet, darkened room, rest or nap, and place a cool cloth or ice pack on your forehead. Staying hydrated by drinking plenty of water is also important. These measures, recommended by the Mayo Clinic, help reduce sensory input that can worsen pain.
Supplements and Complementary Therapies
Certain supplements show evidence for migraine prevention. Magnesium (200–1200 mg daily), riboflavin/vitamin B2 (400 mg daily), and coenzyme Q10 (100 mg three times daily) may reduce the number and severity of attacks. Complementary and alternative medicine (CAM) approaches such as acupuncture, biofeedback, cognitive behavioral therapy, meditation, and yoga can also be effective adjuncts.
Avoiding Triggers and Tracking Patterns
Avoiding known triggers is a critical part of home management. Common dietary triggers include alcohol, caffeine overuse or withdrawal, chocolate, MSG, and tyramine-containing foods like aged cheese and cured meats. Lack of sleep, fatigue, and stress are also frequent culprits. Keeping a headache diary helps identify personal triggers and track treatment effectiveness over time.
Regular exercise can serve as a preventive measure. One study found that 40 minutes of exercise three times weekly reduced attack frequency by nearly one attack per month. Incorporating gentle activities like walking or yoga into a routine can make a meaningful difference.
Finding the Right Specialist in Los Angeles
The UCLA Goldberg Migraine Program is a leading clinic staffed by headache specialists like Dr. Andrew Charles and Dr. Mollie Johnston. It offers comprehensive care that combines clinical research, advanced therapies, and a focus on patient wellness.
The Cedars-Sinai Headache Clinic provides evidence-based approaches, including medication management and nerve blocks, for migraines that do not respond to standard treatments. The clinic is part of a larger neurology and neurosurgery program, indicating a multidisciplinary approach to headache disorders.
For patients near Los Angeles, the California Pain Institute offers a multidisciplinary approach to chronic migraine care. Their treatments include medication management, nerve blocks, trigger point injections, and neuromodulation. Regenerative treatments like platelet-rich plasma (PRP) injections may also be utilized to address migraine pain. Patients receive a customized treatment plan designed by experienced pain medicine physicians.
Beverly Hills Migraine and Pain Management Institute. Led by Dr. Benjamin Taimoorazy, this institute offers cutting-edge therapeutic procedures for chronic painful disorders and headaches.
California Pain Medicine Center. Led by Dr. Joshua Prager, this center provides advanced interventional treatments such as ketamine infusions and spinal cord stimulation for difficult-to-treat migraines.
A comprehensive evaluation by a pain specialist is important for developing a personalized treatment plan that addresses the specific frequency and severity of your migraines.
The Path to Recovery and Remission
For those living with chronic migraine, the hope of returning to a less disruptive form of the condition is a realistic goal. Research indicates that approximately 27% of people with chronic migraine experience remission to episodic migraine each year, meaning a significant reduction in headache frequency. This statistic offers a tangible reason for optimism.
Factors That Improve Remission Chances
Several factors can increase the likelihood of remission. These include a lower baseline headache frequency, consistent use of preventive medications such as topiramate or beta-blockers, and being a non-smoker. Many of these risk factors are modifiable, which means that specific lifestyle changes and a targeted treatment plan can actively support the transition from chronic to episodic migraine.
A key goal in managing migraine is to return control from the disease to the patient, focusing on reducing attack-related disability rather than seeking an absolute cure. This is achieved through personalized treatment plans. At the California Pain Institute, led by an experienced pain medicine physician in Los Angeles, patients receive comprehensive care that combines medical treatment with guidance on lifestyle adjustments and trigger management, all designed to reduce attack frequency and improve quality of life.
With a comprehensive approach that includes preventive medication, trigger management, and consistent medical support, many patients can significantly reduce their migraine burden. The outlook for improvement is encouraging, paving the way from a daily struggle back to a life with fewer interruptions from migraine pain.
A New Era for Stubborn Migraine Care
The treatment landscape for chronic migraine has shifted from borrowed therapies to options designed specifically for the condition. Patients today can choose from CGRP monoclonal antibodies, oral gepants, Botox injections, neuromodulation devices, and targeted surgical procedures, all of which target the underlying mechanisms of migraine rather than just its symptoms.
Accurate diagnosis by a headache specialist is the first step toward an effective, personalized plan. The California Pain Institute offers comprehensive evaluations and access to the full range of these advanced treatments for patients in Los Angeles, helping match each person to the therapy most likely to restore their quality of life.
If stubborn migraines continue to disrupt your daily life, consult with a headache specialist to explore targeted options. Taking that first step can return control from the disease to you.
